FAQs - Genetics

GeneSight analyzes certain genes and predicts their combined influence on each patient's response to psychotropic medications. That helps identify the right medication options for patients to improve outcomes.

GeneSight has shown clinical utility in treating treatment-resistant depression. Clinical studies from primary care and psychiatric care demonstrate a 50% improvement in remission and a 30% improvement in response. The GeneSight Psychotropic test analyzes how genes may affect outcomes with medications commonly prescribed to treat depression, anxiety, ADHD, and other mental health conditions.

Noninvasive prenatal screening can identify your risks for passing down an inherited condition such as cystic fibrosis or spinal muscular atrophy to your baby. Planning for your future family now provides the opportunity to understand potential genetic risks.

Myriad offers three different categories of testing for women: cancer risk assessment with MyRisk, inherited conditions for family planning with ForeSight, and prenatal screening with Prequel.

The Prolaris test from Myriad Genetics gives a personalized risk assessment of a patients’ prostate cancer. Prolaris gives the complete picture on how a patient’s prostate cancer will progress by adding clinically proven information in combination with traditional diagnostic tools.

Patients can use Prequel as early as ten weeks into their pregnancy to identify an increased risk for a chromosome abnormality associated with a certain genetic condition.

Homologous recombination (HR) is the way our body fixes damaged DNA. When homologous recombination is not able to fix damaged DNA, this is called homologous recombination deficiency (HRD). Approximately 50% of all ovarian cancer tumors have homologous recombination deficiency.

MyChoice CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status. It is the most comprehensive tumor test to determine HRD status in patients with ovarian cancer.

BRACAnalysis CDx provides fast and accurate BRCA1/2 results. Germline BRCA1 and BRCA2 status is a critical biomarker to help you determine the appropriate therapy for your patients with breast, ovarian, pancreatic, and prostate cancer.

BRACAnaysis CDx is the only FDA-targeted therapy used to detect mutations in BRCA1 or BRCA2 genes. Mutations in these genes can influence breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Early detection can help you and your healthcare provider the best healthcare decisions for your future care.

Everyone is born with BRCA genes. Normally, the proteins produced by the BRCA1 and BRCA2 genes prevent cells from developing into cancer. When one of these genes becomes ineffective due to an inherited mutation, the cell can no longer prevent tumors from growing, causing an increased risk for cancer.

BRACAnalysis tests for a mutation in specific genes to determine hereditary breast or ovarian cancer risk.

Our Myriad Complete program helps physicians incorporate MyRisk into their practice with education, access to genetic products, results delivered, and consults from genetic counselors.

MyRisk multi-gene panel determines hereditary cancer risk for: Breast, ovarian, colorectal, endometrial, melanoma, pancreatics, gastric, and prostate cancer.

GeneSight analyzes how genes may affect medication outcomes. Results can inform a physician about how a patient may break down or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions.